On the afternoon of September 21, following the conclusion of the forum titled "Everyone's Responsibility: Protecting Minors from Tobacco Use" at the GTNF, 2FIRSTS posed a question to Brian A. King, the Director of the Center for Tobacco Products at the US Food and Drug Administration (FDA): With the rapid development of harm reduction products such as pod-based systems, disposable devices, and open systems, how does the FDA plan to adapt to this evolving category landscape and improve the predictability of regulations?
Brian A. King states that previous generations of nicotine products have not been effective in helping adults quit smoking. In recent years, there have been many innovative e-cigarette products that have been helpful in assisting adult smokers to quit. The FDA shows strong support for this innovation and will strive to adapt to these changes to promote the entry of innovative e-cigarette products into the US market.
Notice
1. This article is provided exclusively for professional research purposes related to industry, technology and policy. Any reference to brands or products is made solely for the purpose of objective description and does not constitute an endorsement, recommendation, or promotion of any brand or product.
2. The use of nicotine products, including but not limited to cigarettes, e-cigarettes, and heated tobacco products, is associated with significant health risks. Users are required to comply with all relevant laws and regulations in their respective jurisdictions.
3. This article is strictly restricted from being accessed or viewed by individuals under the legal age.
Copyright
This article is either an original work by 2Firsts or a reproduction from third-party sources with the original source clearly indicated. The copyright and usage rights of this article belong to 2Firsts or the original source. Unauthorized reproduction, distribution, or any other unauthorized use of this article by any entity or individual is strictly prohibited. Violators will be held legally responsible. For copyright-related matters, please contact: info@2firsts.com
AI Assistance Disclaimer
This article may have utilized AI to enhance translation and editing efficiency. However, due to technical limitations, errors may occur. Readers are advised to refer to the sources provided for more accurate information.
This article should not be used as a basis for any investment decisions or advice, and 2Firsts assumes no direct or indirect liability for any errors in the content.
